CRISPR Therapeutics AG
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programsā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$59.73
Price+1.55%
$0.91
1Y
Price
Market Cap
$5.432b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-26935.3%
EBITDA Margin-23133.1%
Net Profit Margin+21633.1%
Free Cash Flow MarginRevenue
$37.359m
-26.9%
1y CAGR+28211.9%
3y CAGR+63172.6%
5y CAGREarnings
-$467.798m
-41.4%
1y CAGR-79.0%
3y CAGR-7.2%
5y CAGREPS
-$5.43
-40.2%
1y CAGR-80.4%
3y CAGR-13.1%
5y CAGRBook Value
$1.711b
$2.030b
Assets$318.586m
Liabilities$215.452m
DebtDebt to Assets
10.6%
-0.8x
Debt to EBITDAFree Cash Flow
-$325.567m
+38.8%
1y CAGR-42.9%
3y CAGR+37.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company